Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

计划入组 6 人 · 首次发布于 2017 年 12 月 8 日

A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

计划入组 615 人 · 首次发布于 2009 年 11 月 6 日

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

计划入组 312 人 · 首次发布于 2010 年 3 月 1 日

IL-23P40

RTX-IL-12

IL-12-TM

Simcha Il 18, Inc.

United States

Alliance Foundation Trials, LLC

United States

上海生诺医药科技有限公司

Meta-Analysis Confirms Safety and Efficacy of Biologic Switching in Psoriasis Treatment

Werewolf Therapeutics Announces 2025 Milestones for IL-2 and IL-12 INDUKINE Programs

Novel IL-12 Delivery System Shows Promise for Advanced Ovarian Cancer Treatment